Argenx SE (NASDAQ:ARGX) ranks among the best growth stocks to buy and hold for the long term. Following the company’s Q4 results, Oppenheimer increased its price target for Argenx SE (NASDAQ:ARGX) to $1,060 from $1,040 on February 26 while keeping an Outperform rating.

The company reported earnings per share of $8.02, exceeding the projected $5.95. Revenue also came in slightly above expectations, totaling $1.29 billion vs $1.28 billion.

According to Oppenheimer, Vyvgart’s total revenues for the fourth quarter of 2025 totaled $1.29 billion, a 74% increase over the previous year. Vyvgart’s crucial myositis readout in the third quarter may pave the path for an additional 20,000-patient opportunity.

Additionally, on February 26, BofA Securities maintained a Buy rating on Argenx SE (NASDAQ:ARGX) and increased its price objective from $1,006 to $1,013. The firm ranked Argenx as a top pick and kept its Vyvgart sales projection flat compared to the fourth quarter of 2025 for the coming first-quarter 2026 earnings.

Argenx SE (NASDAQ:ARGX) is a Netherlands-based global biotechnology company focused on developing, manufacturing, and commercializing antibody-based therapies for severe autoimmune diseases and cancers.

While we acknowledge the potential of ARGX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey on Google News.